

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10602330
	Filing Date	2003-06-23
	First Named Inventor	Clarence Ahlem
	Art Unit	1617
	Examiner Name	Barbara Radio
	Attorney Docket Number	202.2D2

/BB/	1	A.L. Copley et al., On physiological microthromboembolization as the primary platelet function: elimination of invaded particles from the circulation and its pathogenic significance, <i>Thromb. Res.</i> , 8(3):251-262, 1976	<input type="checkbox"/>
/BB/	2	J.G. Hirsch, Comparative bactericidal activities of blood serum and plasma serum, <i>J. Exp. Med.</i> , 112:15-22, 1960	<input type="checkbox"/>
/BB/	3	J.E. Layton et al., Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor, <i>Blood</i> , 74(4):1303-1307, 1989 Aging and innate immune cells	<input type="checkbox"/>
/BB/	4	T.P. Plackett et al., Aging and innate immune cells, <i>J. Leukocyte Biol.</i> , 76:291-299, 2004	<input type="checkbox"/>
/BB/	5	J.J. Ramsey et al., Dietary restriction and aging in rhesus monkeys: the University of Wisconsin study, <i>Experimental Gerontol.</i> 35:1131-1149, 2000	<input type="checkbox"/>
/BB/	6	J.F. Seymour et al., Mice lacking both granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF have impaired reproductive capacity, perturbed neonatal granulopoiesis, lung disease, amyloidosis, and reduced long-term survival, <i>Blood</i> , 90(8):3037-3049, 1997	<input type="checkbox"/>
/BB/	7	D.R. Stickney et al., 5-Androstenediol improves survival in clinically unsupported rhesus monkeys with radiation-induced myelosuppression, <i>International Immunopharmacology</i> , 7:—, 2007, in press	<input type="checkbox"/>
/BB/	8	A. W. Wognum et al., Differential expression of receptors for interleukin-3 on subsets of CD34-expressing hematopoietic cells of rhesus monkeys, <i>Blood</i> , 86(2):581-591, 1995	<input type="checkbox"/>
/BB/	9	F.S.F. Kaya-Aerts et al., HE2100 (5-Androstan-3b,17b-diol) after cytoreductive total body irradiation of rhesus monkeys promotes the recovery of immature CD34+ bone marrow cells, accelerates platelet, granulocyte and red cell reconstitution, and alleviates neutropenia and anemia, <i>Blood (ASH Annual Meeting Abstracts)</i> 106: abstract 4203, 2005	<input type="checkbox"/>
/BB/	10	Goans, et al., Early dose assessment following severe radiation accidents, <i>Health Physics</i> , 72(4), pps.513-8, 1997	<input type="checkbox"/>
/BB/	11	Macintyre, A., et al., Weapons of mass destruction events with contaminated casualties, <i>MAMA</i> , 283(2) pps. 242-9, 2000	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10602330
Filing Date	2003-06-23
First Named Inventor	Clarence Ahlem
Art Unit	1617
Examiner Name	Barbara Radio
Attorney Docket Number	202.2D2

/BB/	12	Singh, V, et al., Effects of whole-body gamma irradiation and 5-androstanediol administration on serum G-CSF, Immunopharmacology and Immunotoxicology, 27, pps 521-34, 2005	<input type="checkbox"/>
/BB/	13	Whitnall, M., et al., Molecular specificity of 5-androstanediol as a systemic radioprotectant in mice, Immunopharmacology and Immunotoxicology, 27, pps 15-32, 2005	<input type="checkbox"/>
/BB/	14	Diagnosis and Treatment of Radiation Injuries, Safety Reports series No. 2 (1998), Vienna: International Atomic Energy Agency, pp. 13	<input type="checkbox"/>
/BB/	15	Stickney, D. et al., 5-androstanediol stimulates multilineage hematopoiesis in rhesus monkeys with radiation-induced myelosuppression, Int'l Immunopharmacology, 6, pp. 1706-13, 2006	<input type="checkbox"/>
/BB/	16	MacVittie, T., et al, Combinaiton therapy for radiation-induced bone marrow aplasia in nonhuman primates using synthokine SC-55494 and recombinant human granulocyte colony-stimulating factor, Blood, 887(10), pps 4129-35, 1996	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Barbara Radio/	Date Considered	05/08/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10602330
Filing Date	2003-06-23
First Named Inventor	Clarence Nathaniel Ahlem
Art Unit	1617
Examiner Name	Barbara Radio
Attorney Docket Number	202.2D2

**U.S.PATENTS****Remove**

Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/BB/	1	5641768		1997-06-24	Loria	
/BB/	2	6432940		2002-08-13	Labrie	
/BB/	3	6884795		2005-04-26	Labrie	

If you wish to add additional U.S. Patent citation information please click the Add button.

**Add****U.S.PATENT APPLICATION PUBLICATIONS****Remove**

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/BB/	1	20050256095		2005-11-17	Ahlem, et al	
/BB/	2	20050282732		2005-12-22	Ahlem, et al	
/BB/	3	20060063749		2006-03-13	Ahlem, et al	

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>( Not for submission under 37 CFR 1.99)</i>		Application Number	10602330
		Filing Date	2003-06-23
		First Named Inventor	Clarence Nathaniel Ahlem
		Art Unit	1617
		Examiner Name	Barbara Radio
		Attorney Docket Number	202.2D2

/BB/	4	20060079492		2006-04-13	Ahlem, et al	
/BB/	5	20070014719		2007-03-20	Reading, et al	
/BB/	6	20070053832		2007-03-08	Frincke, et al	

If you wish to add additional U.S. Published Application citation information please click the Add button

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1		<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

#### EXAMINER SIGNATURE

Examiner Signature	/Barbara Radio/	Date Considered	05/08/2007
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.